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Optimization and validation of an RP-HPLC method for the 
estimation of 6-mercaptopurine in bulk and pharmaceutical 
formulations
Vanita Somasekhar*
KLE University’s College of Pharmacy, Bangalore, Karnataka, India
A reverse phase HPLC method is described for the determination of 6-mercaptopurine in bulk and tablets. 
Chromatography was carried on a C18 column using a mixture of acetonitrile and 0.05 mol/L sodium 
acetate buffer (10:90 v/v) as the mobile phase at a flow rate of 1 mL/min-1 with detection at 324 nm. 
The retention time of the drug was 3.25 min. The detector response was linear in the concentration of 
0.01-5 μg/mL. The limit of detection and limit of quantification were 17 and 52 ng/mL respectively. 
The method was validated by determining its sensitivity, linearity, accuracy and precision. The proposed 
method is simple, economical, fast, accurate and precise and hence can be applied for routine quality 
control of mercaptopurine in bulk and tablets.
Uniterms: 6-Mercaptopurine/determination. High perfomance liquid chromatography/reverse phase/
quantitative analysis. Pharmaceutical formulations/quality control
Descreve-se método de CLAE em fase reversa para a determinação de mercaptopurina a granel e em 
comprimidos. A cromatografia foi realizada em coluna C18, utilizando mistura de acetonitrila em tampão 
acetato de sódio 0,05 mol/L (10:90 v/v) como fase móvel, com fluxo de 1 mL/min e detecção a 324 nm. 
O tempo de retenção do fármaco foi de 3,25 min. A resposta do detector foi linear na concentração de 
0,01-5 μg/mL. O limite de detecção e o limite de quantificação foram de 17e 52 ng/mL, respectivamente. 
O método foi validado pela determinação de sua sensibilidade, linearidade, acurácia e precisão. O método 
proposto é simples, econômico, rápido, acurado e preciso e, então, pode ser aplicado para controle de 
qualidade de rotina da mercaptopurina em batelada e em comprimidos. 
Unitermos: Mercaptopurina/determinação. Cromatografia líquida de alta eficiência/fase reversa/análise 
quantitativa. Formulações farmacêuticas/controle de qualidade.
INTRODUCTION
6-Mercaptopurine (Figure 1) is an anti-cancer 
(“antineoplastic” or “cytotoxic”) chemotherapy drug. In 
Cancerous tumors, cell division is no longer controlled 
as it is in normal tissue. When “Normal” cells come into 
contact with like cells, they stop dividing. This mechanism 
is called contact inhibition. Cancerous cells do not have 
this ability. Chemotherapy kills cancer cells by halting 
cell division. Chemotherapy has been found to be most 
effective at killing cells that are rapidly dividing. But, since 
chemotherapy cannot distinguish between the cancerous 
cells and the normal cells, both are affected. Hence side 
effects occur until the “normal” cells grow back and be 
healthy.
6-Mercaptopurine belongs to  the class  of 
chemotherapy drugs called “antimetabolites”. When 
antimetabolites are incorporated into cellular metabolism 
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FIGURE 1 – Chemical Structure of 6-MP.
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by cells, they are unable to divide. Antimetabolites attack 
cells at very specific phases in the cycle. 6-Mercaptopurine 
is converted to 6-thioinosinic acid, which acts as an 
antimetabolite to inhibit synthesis of adenine and guanine 
and also to prevent conversion of purine bases into 
nucleotides. Some 6-mercaptopurine is also converted to 
thioguanine, which is incorporated into both DNA and 
RNA to generate defective nucleic acids. Thus the synthesis 
of nucleic acid and its functions are impaired in several 
ways and cell mitosis is inhibited. The purine antagonist 
6-mercaptopurine (6-MP) has been used as a chemotherapy 
drug and is usually given orally. When higher doses are 
required, the drug may be given intravenously. Patients 
suffering from acute lymphocytic or myelocytic leukemia, 
lymphoblastic leukemia (especially in childhood cases) 
and acute myelogenous and myelomonocyticleukemias are 
often given 6-MP in combination with other chemotherapy 
drugs. In addition to its role in cancer treatment, 6-MP 
is used to treat patients suffering from a variety of 
inflammatory bowel diseases. The drug is also used to 
prevent rejection following organ transplants.
Since 6-MP is widely used in chemotherapy, it is 
important to develop and validate analytical methods for 
its determination in pharmaceutical dosage forms. Review 
of literature has revealed that all methods reported for 
the estimation of 6-MP are useful in estimating 6-MP 
in biological samples (Sorouraddin et al., 2011; Hawwa 
et al., 2009; Umrethia et al., 2006; Oliveira et al., 2004; 
Su et al., 1999; Mawatari et al., 1998; Sahnoun et al., 
1990; Erdmann, Chan, Canafax, 1988; Rudy et al., 1988; 
Migulla, Prumke, Huller, 1987). So far no systematic 
HPLC method has been reported for determination 
of 6-MP in pharmaceutical formulations. This paper 
reports a rapid and sensitive HPLC method with UV 
detection, useful for routine quality control of 6-MP in 
pharmaceutical formulations. The method was validated 
by parameters such as linearity, accuracy, precision and 
robustness.
MATERIAL AND METHODS
Apparatus
The HPLC used consisted of Hitachi chromatographic 
system equipped with a Hitachi pump L-7110, Rheodyne 
universal injector 7725 and Hitachi L-7400 UV-visible 
detector. The chromatographic studies were performed 
using Phenomenex® C18, 5 μm, 250 mm x 4.6 mm i.d. 
column, at ambient temperature. Peak area integration 
was performed using Winchrom software. A Shimadzu 
model 1700 double beam UV-visible spectrophotometer 
with a pair of 10 mm matched quartz cells was employed 
for determination of absorption maximum.
Reagents and chemicals
HPLC grade acetonitrile and glacial acetic acid 
were obtained from Rankem (Mumbai, India) and sodium 
acetate (A.R. grade) was obtained from Sd Fine Chemicals, 
Mumbai, India. Pure sample of drug was obtained from 
Sigma Aldrich, India. Ultra-pure water obtained from 
Milli-Q academic system (Millipore Pvt. Ltd., Bangalore, 
India) was used to prepare all solutions for the method.
Chromatographic conditions
The process was carried out on C18 column (5 μm, 
250 x 4.6 mm, i.d) using the mobile phase consisting of 
acetonitrile and 0.05 M sodium acetate buffer in the ratio 
10:90 with pH adjusted to 6.8 using HPLC grade glacial 
acetic acid at a flow rate of 1 mL/min. Wavelength was 
fixed at 324 nm. The mobile phase was filtered through 
0.45 μm membrane filter and degassed.
Preparation of solutions
Stock standard solution of the pure drug was 
prepared by dissolving 100 mg of 6-MP in 100 mL 
volumetric flask using 0.1 mol/L sodium hydroxide. Then 
the volume was made up to the mark with the same solvent 
to give a final concentration of 1000 μg/mL. Nine standard 
solutions of 6-MP in the range of 0.01-5.0 μg/mL (0.01, 
0.05, 0.1, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 μg/mL) were prepared 
by subsequent dilution with mobile phase.
Validation
Three series of standard solutions in the range of 
0.01-5.0 μg/mL were prepared and analyzed as described 
above. Calibration curves were constructed using three 
series of standard 6-MP solutions in the range of 0.01-
5.0 μg/mL. Peak area was recorded for all the peaks and 
a calibration graph was obtained by plotting peak area 
versus concentration of 6-MP. To establish the accuracy 
and intra-day and inter-day precision of the method, six 
replicate solutions at three different concentrations (0.5, 
1.0, 2.5 μg/mL) were assayed on single day and three 
separate days.
Assay method
Twenty tablets were weighed, crushed and an amount 
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of powder equivalent to100 mg of 6-MP was accurately 
weighed, transferred to a 100 mL volumetric flask, made 
up to volume with 0.1 mol/L sodium hydroxide and placed 
in an ultrasonic bath for 20 min. After filtration through a 
0.45 μm membrane filter, the solution was suitably diluted 
with mobile phase to obtain the required concentration.
20 μL of solution was injected into the HPLC system 
to obtain the chromatograms for the standard drug solution 
and the sample solution.
A steady baseline was recorded with the optimized 
chromatographic conditions. The standard solution of 
6-MP was injected and the chromatogram recorded. 
The retention time of 6-MP was found to be 3.25 min. 
The sample solution prepared from the tablets was then 
injected and the amount of drug present was calculated 
from the calibration curve.
RESULTS AND DISCUSSION
Chromatographic conditions
Various compositions of mobile phase consisting of 
acetonitrile and sodium acetate (50:50 to 10:90) were used 
in the study and the composition of 10:90 was selected as 
it gave best elution, reasonable retention time and least 
tailing. A pH 6.8 was found to give the best elution, while 
increased tailing was observed at lower pH values. Flow 
rates between 0.5 and 1.5 were studied and a flow rate of 
1 ml/min was found to give a good separation time and 
peak shape.
The typical chromatogram obtained for 6-MP is 
presented in Figure 2.
Linearity
Calibration curves were constructed using three 
series of standard 6-MP solutions in the range of 
TABLE I - Statistical data of calibration curves of mercaptopurine
Parameters Mercaptopurine
Linearity
Regression equation
Standard deviation of slope
Relative standard deviation of slope 
(%)
Standard deviation of intercept
Correlation coefficient (r)
Limit of Detection (LOD)
Limit of Quantitation (LOQ)
0.01 – 5 μg/mL 
Y = 1E+06X + 51613 
0.00 
0.00 
5177.8 
0.999 
17 ng/mL 
52 ng/mL
FIGURE 2 - Chromatogram of 6-MP.
0.01-5.0 μg/mL. The equation of linear regression and 
statistical data are presented in Table I. The linearity of 
the calibration curve was validated by the high value of 
the correlation coefficient (r=0.9997).
Limit of detection (LOD) and limit of 
quantification (LOQ)
The limit of detection and the limit of quantification 
are defined as LOD=3.3 σ/s and LOQ=10 σ/s respectively, 
where σ denotes standard deviation of y-intercepts of 
regression lines and s denotes slope of the corresponding 
calibration curve (ICH 2005).
The limit of detection was determined as 17 ng/mL.
The limit of quantification was determined as 
52 ng/mL.
Precision
The assay was investigated with respect to system 
suitability test, method precision and intermediate 
precision. The system suitability test and method 
precision were carried out to monitor repeatability and 
reproducibility.
In order to measure repeatability of the system 
(system suitability test), five consecutive injections were 
made and the results were evaluated by considering peak 
area values of 6-MP. The precision values with their R.S.D. 
are shown in Table II. The results in Table II indicate that 
the R.S.D.(%) is less than 2%.
Three different concentrations of 6-MP were 
analyzed in three independent series in the same day 
(intra-day precision) and three consecutive days (inter-
day precision), within each series every sample was 
injected six times. The R.S.D. values of intra- and 
inter-day studies (Table II) varied from 0.16 to 0.79% 
showing that the intermediate precision of the method 
was satisfactory.
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Accuracy and recovery studies
The accuracy of a method is expressed as the 
closeness of agreement between the value found and the 
value that is accepted as a reference value. It is determined 
by calculating the percent difference (bias%) between the 
measured mean contents and the corresponding nominal 
contents(Braggio et al., 1996). Table II shows the results 
obtained for intra- and inter-day accuracy.
The accuracy of the proposed method was also tested 
by recovery experiments. Recovery experiments were 
performed by taking different sample concentrations and 
spiking with 6-MP at two different concentration levels 
(50% and 100% 6-MP). Six samples were prepared for 
each recovery level. Samples were treated as described 
in the procedure for sample preparations. The results 
obtained are shown in Table III, from which it is clear 
that both the recoveries and repeatabilities are excellent.
Robustness
Robustness relates to the capacity of the method 
to remain unaffected by small but deliberate variations 
introduced into the method parameters. Influences of small 
changes in the mobile phase composition (±10%), pH (±0.5) 
and flow rate (±10%) were studied to determine robustness 
of the method. Peak areas and retention time changes were 
observed. It was found that Peak area values and retention 
time values varied by less than 2%. Despite the changes 
in retention time there was no problem for quantification.
Specificity
The specificity test of the proposed method 
demonstrated that the excipients from marketed capsules 
did not interfere in the drug peak. Furthermore, well-
resolved peak indicates the specificity of the method 
(Figure 2).
Analysis of pharmaceutical formulation
In order to evaluate the applicability and reliability 
of the proposed methodology, it was applied to the 
determination of 6-MP in tablets. Satisfactory results were 
obtained and were found to be in agreement with label 
claims (Table IV).
CONCLUSION
T h e  p r o p o s e d  h i g h - p e r f o r m a n c e  l i q u i d 
chromatographic method has been evaluated for 
linearity, precision, accuracy, specificity and proved to be 
TABLE II - Precision and accuracy of method for determination of 6-MP (n=18; six sets for 3d)
Concentration 
Taken (μg/mL)
Concentration found 
(mean ± S.D.)  
(μg/mL)
Precisiona 
(R.S.D (%))
Accuracyb 
(bias %)
Intra-day (n=6) 
0.5  
1.0 
2.5 
Inter-day (n=18) 
 0.5  
1.0 
2.5
 
0.5 ± 0.029 
 1.00 ± 0.016 
2.51 ± 0.034 
 
0.499 ± 0.019 
0.999 ± 0.057 
2.495 ± 0.027
 
0.29 
0.66 
0.79 
 
0.16 
0.20 
0.32
 
0.0 
0.0 
0.4 
 
0.2 
0.1 
0.2
a R.S.D.(%) : relative standard deviation; bbias(%) : [(found – taken)/taken] x 100
TABLE III- Recovery Data for the Proposed RP-HPLC method (n=6)
Pharmaceutical formulations
Amount (μg/mL)
% Recovery ±R.S.D.
Taken + Added Found* ± S.D.
Tablets I 
Tablets II 
Tablets III 
Tablets IV
0.5 + 0.25 
0.5 + 0.5 
1.0 + 0.5 
1.0 + 1.0
0.751 ± 0.002 
1.002 ± 0.006 
1.500 ± 0.007 
2.008 ± 0.008
100.13 ± 0.326 
100.18 ± 0.617 
100.00 ± 0.471 
100.40 ± 0.417
*Average of six determinations
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TABLE IV - Analysis of 6-MP from pharmaceutical formulations by proposed method
Sample Labelled amount (mg) Amount found* ± S.D. % Recovery ± R.S.D.
Tablets I 
Tablets II 
Tablets III 
Tablets IV
50 
50 
50 
50
50.13 ± 0.329 
49.97 ± 0.226 
50.08 ± 0.344 
50.07 ± 0.187
100.27 ± 0.657 
99.94 ± 0.452 
100.15 ± 0.687 
100.14 ± 0.373
*Average of six determinations
convenient and effective for the quality control of 6-MP 
in given application. The measured signal was shown to 
be precise, accurate, and linear over the concentration 
range tested (0.01-5.0 μg/mL) with a correlation 
coefficient better than 0.9997. Moreover, the lower solvent 
consumption leads to a cost effective and environmentally 
friendly chromatographic procedure. Thus, the proposed 
methodology is rapid, selective, requires a simple sample 
preparation procedure, and represents a good procedure 
of 6-MP determination in pharmaceutical dosage forms.
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